Elan Prialt Clears FDA, Will Launch In Late January
This article was originally published in The Pink Sheet Daily
Executive Summary
Intrathecal therapy is indicated for "the management of severe chronic pain in patients…who are intolerant or refractory to other treatment." Elan will promote the non-opioid therapy with 40 to 50 sales reps targeting 3,000 doctors.